David Hirsch is a founder and Managing Director of Longitude Capital where he focuses on investments in biotechnology. Previously, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. In addition to serving on the Board of Collegium Pharmaceutical, Inc., he also serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitude’s investments in Amarin and Corcept Therapeutics. Dr. Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a B.A. in Biology from The Johns Hopkins University.